sacituzumab govitecan (Trodelvy) Report issue

Biologics mAb ADC Approved FDA Fast Track FDA Breakthrough Therapy FDA Accelerated Approval FDA

Active Ingredient History

  • Now
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Payload: SN-38
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1530.8000 - $2002.3900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

immu-132 | sacituzumab govitecan


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue